In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
News|Articles|March 9, 2026
Mixed signals and mounting frustrations: ophthalmologists on dry eye disease
Author(s)Matt Hoffman
Ophthalmologists report dry eye’s mixed mechanisms, symptom-driven diagnosis, uneven treatment response, and payer hurdles—what needs fixing next.
Advertisement
Advertisement
A recent survey of practicing ophthalmologists conducted by Ophthalmology Times revealed a clinical landscape defined by diagnostic ambiguity, therapeutic limitation, and systemic friction. Although the survey was limited to a sample size of 17 physicians, the responses underscore that despite a growing armamentarium of treatment options, dry eye disease (DED) remains one of the most challenging and contested conditions in ophthalmic practice.
Related to this article
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
Advertisement
Advertisement